Virological outcome measures during analytical treatment interruptions in chronic HIV-1 infected patients

Author:

Fehér Csaba123,Leal Lorna23,Plana Montserrat3,Climent Nuria3,Crespo Guardo Alberto3,Martínez Esteban23,Castro Pedro234,Díaz-Brito Vicens2,Mothe Beatriz567,López Bernaldo De Quirós Juan Carlos89,Gatell Josep María2310,Aloy Patrick111,García Felipe23

Affiliation:

1. Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute for Science and Technology, Barcelona, Spain

2. Infectious Diseases Department, Hospital Clinic of Barcelona – HIVACAT, University of Barcelona, Barcelona, Spain

3. Retrovirology and Viral Immunopathology Laboratory, AIDS Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) – HIVACAT, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain

4. Medical Intensive Care Unit, Hospital Clinic of Barcelona, Barcelona, Spain

5. IrsiCaixa AIDS Research Institute, Badalona, Spain

6. Infectious Diseases Department, Hospital Germans Trias i Pujol, Badalona, Spain

7. University of Vic – Central University of Catalonia, Vic, Spain

8. HIV/Infectious Diseases Unit. Hospital General Universitario Gregorio Marañón, Madrid, Spain

9. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid. Spain

10. Senior Global Medical Director. ViiV Healthcare, Tres Cantos, Spain

11. Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

Abstract

Abstract Background Analytical treatment interruptions (ATI) are essential in research on HIV cure. However, the heterogeneity of virological outcome measures used in different trials hinders the interpretation of the efficacy of different strategies. Methods A retrospective analysis of viral load (VL) evolution in 334 ATI episodes in chronic HIV-1 infected patients collected from 11 prospective studies. Quantitative [baseline VL, set point, delta set point, VL and delta VL at given weeks after ATI, peak VL, delta peak VL, and area under the rebound curve], and temporal parameters [time to rebound (TtR), set point, peak, and certain absolute and relative VL thresholds] were described. Pairwise correlations between parameters were analyzed, and potential confounding factors (sex, age, time of known HIV infection, time on ART, and immunological interventions) were evaluated. Results Set point was lower than baseline VL (median delta set point -0.26. p< 0.001). This difference was >1 log10 copies/mL in 13.9% of the cases. Median TtR was 2 weeks; no patients had undetectable VL at week 12. Median time to set point was 8 weeks: by week 12, 97.4% of the patients had reached the set point. TtR and baseline VL were correlated with most temporal and quantitative parameters. The variables independently associated with TtR were baseline VL and the use of immunological interventions. Conclusions TtR could be an optimal surrogate marker of response in HIV cure strategies. Our results underline the importance of taking into account baseline VL and other confounding factors in the design and interpretation of these studies.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3